HYBIO PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.73 CNY | +4.09% |
|
+6.60% | +1.10% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 704M 97.48M | Sales 2023 | 431M 59.7M | Capitalization | 11.99B 1.66B |
|---|---|---|---|---|---|
| Net income 2022 | -371M -51.35M | Net income 2023 | -514M -71.14M | EV / Sales 2022 | 24.2 x |
| Net Debt 2022 | 1.54B 213M | Net Debt 2023 | 1.67B 230M | EV / Sales 2023 | 31.7 x |
| P/E ratio 2022 |
-41.9
x | P/E ratio 2023 |
-23.4
x | Employees | 975 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.56% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.09% | ||
| 1 week | +6.60% | ||
| Current month | +6.60% | ||
| 1 month | +23.14% | ||
| 3 months | +28.80% | ||
| 6 months | -27.16% | ||
| Current year | +1.10% |
1 week
12.73
13.98
1 month
10.0513.98
Current year
8.9014.95
1 year
8.6620.88
3 years
4.2624.44
5 years
4.2624.44
10 years
4.2652.76
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Pin Xiang
CEO | Chief Executive Officer | 51 | 19-05-30 |
Hong Hong Tu
DFI | Director of Finance/CFO | 48 | 21-07-07 |
Yang Ming Tang
BRD | Director/Board Member | 46 | 21-01-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lian Zhong
BRD | Director/Board Member | 63 | 21-08-22 |
Shao Gui Zeng
CHM | Chairman | 56 | 09-10-26 |
Shao Qiang Zeng
BRD | Director/Board Member | 53 | 09-10-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 13.73 | +4.09% | 90,902,080 |
| 24-05-07 | 13.19 | +0.30% | 69,579,870 |
| 24-05-06 | 13.15 | +2.10% | 89,328,820 |
| 24-04-30 | 12.88 | +5.31% | 64,577,610 |
End-of-day quote Shenzhen S.E., May 07, 2024
More quotes
Hybio Pharmaceutical Co., Ltd. is a China-based company principally involved in the development, manufacture and distribution of chemical synthetic polypeptide pharmaceuticals. The Companyâs products include polypeptide preparations, polypeptide active pharmaceutical ingredients (APIs) and customer polypeptide, among which the preparation products include thymopentin for injection, somatostatin for injection, desmopressin for injection and terlipressin for injection, among others. Through its subsidiaries, the Company's newly added products are pharmaceutical packaging products, medical devices and solid products. The Company is also engaged in provision of related technological services.
Sector
Pharmaceuticals
Calendar
2024-05-17
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +1.10% | 1.68B | |
| +18.67% | 43.74B | |
| +21.99% | 22.26B | |
| +16.41% | 14.9B | |
| +9.03% | 13.39B | |
| +40.48% | 12.12B | |
| -9.64% | 6.92B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.41% | 5.47B |
- Stock Market
- Equities
- 300199 Stock